首页> 外文期刊>Regulatory peptides. >Fasting plasma levels of nesfatin-1 in patients with type 1 and type 2 diabetes mellitus and the nutrient-related fluctuation of nesfatin-1 level in normal humans.
【24h】

Fasting plasma levels of nesfatin-1 in patients with type 1 and type 2 diabetes mellitus and the nutrient-related fluctuation of nesfatin-1 level in normal humans.

机译:1型和2型糖尿病患者的空腹nesfatin-1水平和正常人nesfatin-1水平的营养相关波动。

获取原文
获取原文并翻译 | 示例
           

摘要

The novel satiety factor nesfatin-1 has been shown to decrease food intake and body weight in rodents after i.c.v. injection. However, no further developments regarding the true patho-physiological relevance of nesfatin-1 in obesity and type 1 diabetes mellitus (T1 DM) and type 2 diabetes mellitus (T2 DM) have been reported. A recent study by Stengel et al. demonstrated that a down-regulation of NUCB2 mRNA in gastric endocrine cells was observed after 24-h fasting. They raised the possibility that nesfatin/NUCB2 gene expression may be regulated by nutritional status, suggesting that nesfatin-1 in the stomach might play a role in satiety. In the present study, fasting levels in plasma nesfatin-1, insulin and glucose were measured and analyzed in healthy subjects and in patients with T1 DM and T2 DM. Plasma nesfatin-1 levels were measured 6 times before and after oral glucose ingestion in healthy subjects. No sex differences in plasma nesfatin-1 were found. The mean fasting plasma nesfatin-1 levels were slightly but not significantly higher in T1 DM patients compared to healthy subjects. However, fasting plasma nesfatin-1 levels were significantly lower in T2 DM patients compared to healthy subjects and T1 DM patients. Plasma nesfatin-1 did not change acutely, although a small rise in circulating nesfatin-1 occurred within 30 min after the beginning of an oral glucose ingestion (from a mean basal value of 0.99+/-0.23 ng/ml to a maximum of 1.08+/-0.24 ng/ml). No significant difference in plasma nesfatin-1 before and after an oral glucose was observed. In conclusion, we showed that fasting nesfatin-1 was significantly lower in T2 DM patients compared to healthy subjects and T1 DM patients. The significance of this result is unclear but the reduction in fasting nesfatin-1 may be one of the appetite-related hormones involved in diabetic hyperphagia. In addition, neither glucose nor saline ingestions affected plasma nesfatin-1, suggesting that gastric chemosensation is not sufficient for the nesfatin-1 response under the present conditions.
机译:新型饱足因子nesfatin-1已被证明可以在静脉内注射后降低啮齿动物的食物摄入量和体重。注射。但是,尚无关于nesfatin-1与肥胖和1型糖尿病(T1 DM)和2型糖尿病(T2 DM)的真正病理生理相关性的进一步进展的报道。 Stengel等人的最新研究。结果表明,禁食24小时后,胃内分泌细胞中NUCB2 mRNA的表达下调。他们提出了nesfatin / NUCB2基因表达可能受营养状况调节的可能性,表明胃中的nesfatin-1可能在饱腹感中起作用。在本研究中,对健康受试者以及患有T1 DM和T2 DM的患者的血浆nesfatin-1,胰岛素和葡萄糖的禁食水平进行了测量和分析。在健康受试者口服葡萄糖摄取前后,测量了6次血浆nesfatin-1水平。在血浆nesfatin-1中未发现性别差异。与健康受试者相比,T1 DM患者的平均空腹血浆nesfatin-1水平略高但不明显。但是,与健康受试者和T1 DM患者相比,T2 DM患者的空腹血浆nesfatin-1水平显着降低。血浆nesfatin-1并未发生剧烈变化,尽管口服葡萄糖摄入开始后30分钟内循环nesfatin-1出现了小幅上升(从平均基础值0.99 +/- 0.23 ng / ml到最大值1.08) +/- 0.24 ng / ml)。口服葡萄糖之前和之后,血浆nesfatin-1均无显着差异。总之,我们显示与健康受试者和T1 DM患者相比,T2 DM患者的禁食nesfatin-1显着降低。此结果的意义尚不清楚,但禁食nesfatin-1的减少可能是与糖尿病性食欲亢进有关的食欲相关激素之一。另外,葡萄糖和盐水的摄取均不影响血浆nesfatin-1,这表明在当前条件下胃化学感受器不足以使nesfatin-1应答。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号